Nav: Home

Genetic fixer-uppers may help predict bladder cancer prognosis

May 15, 2018

HERSHEY, Pa. -- Mutations in genes that help repair damage to DNA may aid in predicting the prognosis of patients with bladder and other related cancers, according to researchers.

The researchers found that bladder cancer patients who had mutations in their ATM or RB1 genes -- proteins that help repair DNA damage when they're functioning normally -- tended not to live as long as patients without the mutations.

Dr. Monika Joshi, assistant professor of medicine, Penn State Cancer Institute, said that as researchers try to design better treatments for cancer patients, it's important for them to find biomarkers that can help researchers understand the differences between patients and their prognoses.

"We're coming to realize that not every cancer patient is the same," Joshi said. "We see some patients responding to therapies, while others do not. Treatments like chemotherapy and immunotherapy, do not have a 100 percent response rate. So we're trying to delve deeper to better understand biological differences between patients."

According to the researchers, mutations or defects in DNA repair genes -- like ATM and RB1 -- play a role in tumor growth and how the cancer responds to treatment, and are often found in patients with bladder cancer.

Previous research has also shown a connection between these mutated DNA repair genes and patients who respond better to certain types of chemotherapy. Joshi said this could be because the drug used in the treatment works better in cells when they're dividing.

"These genes help repair damage to the DNA, but when these genes are mutated, they actually reduce the repair response, allowing tumor cells with defective DNA to proliferate," Joshi said. "And when those tumor cells are proliferating, at that point they may be more susceptible to certain treatments like chemotherapy."

Joshi and the other researchers wanted to better examine how ATM and RB1 genes predicted the outcomes of patients with bladder cancer and analyzed information from two separate data sets.

The first or "discovery" data set included information about 130 bladder cancer patients from the Cancer Genome Atlas, a public database of cancer and genomic data. The second or "validation" data set included information about 81 patients with bladder cancer or other related cancers from three academic medical centers.

Mutations in the ATM or RB1 genes were found in 24 percent of patients in the discovery data set, and 22.2 percent of patients in the validation data set. Patients in both data sets with these mutations also tended not to live as long.

After two years, a significant difference was observed in the discovery data set in which about 15 percent of patients with mutations were still alive as compared to 45 percent of patients without mutations. A similar (although non-statistically significant) trend was noted in the validation data set, where about 50 percent of patients with mutations were still alive as opposed to 60 percent of patients without mutations.

Joshi said the results -- recently published in the journal Oncotarget -- bring up interesting questions when compared with the findings of previous studies.

"It would be interesting to further study these two specific genes and see what about them may make patients fare worse," Joshi said.

While it may be discouraging for patients to discover they have a gene that may predict a poor prognosis, Joshi added that the findings also have the potential to help researchers decide where to focus their work in the future.

"If we know patients with this gene have a poorer prognosis, we can focus our efforts to learn more about why this might be happening so we can improve therapies for these patients," Joshi said. "We might not have all the answers after this study, but I think it helps pave the way for future development of targeted therapies in bladder cancer."
-end-
Ming Yin, Monali Vasekar and Joseph J. Drabick, all of the Penn State Cancer Institute; Petros Grivas, University of Washington; Hamid Emamekhoo, University of Wisconsin Carbone Cancer Center; Prateek Mendiratta, Cleveland Clinic Taussig Center Institute; Siraj Ali, Foundation Medicine; JoAnn Hsu, City of Hope Comprehensive Cancer Center; and Sumanta Pal, City of Hope Comprehensive Cancer Center, also participated in this research.

This study received no specific funding.

Penn State

Related Cancer Articles:

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
More Cancer News and Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...